COVID-19 Vaccinations
Vaccines available at the Mattoon, Charleston and Effingham Walk-In Clinics.
Pfizer Bivalant vaccine is available for people age 12 and older at the Mattoon and Charleston Walk-In Clinics. Those who have not received any COVID-19 vaccines in the past will require just one vaccine. Those who have received previous vaccines two more more months ago, can receive one Bivalant booster. Those who are older than 65 and immunocompromised can receive another Bivalent vaccine at four months or more from their last injection. This vaccine is FREE and available from 7 am to 7 pm, Monday through Friday and 8 am to 3 pm on Saturday and Sunday. No appointment is needed. The vaccine is also available at the Effingham Walk-In Clinic from 1 to 6 pm on Thursdays by appointment only.
- Charleston Walk-In Clinic • 2040 Lincoln Ave, Suite 100 • 217-345-2030
- Mattoon Walk-In Clinic • 200 Dettro Dr. • 217-238-3000
- Effingham Walk-In Clinic • 1303 W. Evergreen Ave., Suite 100 • 217-540-6123
Are you on the fence about getting the COVID-19 Vaccination?
Talk to your primary care doctor. If you want a vaccine or if you have questions, ask your provider.
What to Bring to Appointment
Participants will be required to bring their vaccination card, (paper version, not electronic) driver’s license and an insurance card if they have one before the vaccine can be administered. There is no charge for the vaccination, however insurance carriers may be charged for its administration.
Vaccination
Participants will be required to complete a form prior to receiving the vaccine and will be required to wait about 15 minutes post vaccination to watch for any reaction to the injection. An appointment for a second dose will be made at this time. Participants will receive a vaccination card. Keep this card in a safe place as it may be needed for future travel or other purposes. The information will be uploaded into the state’s I-CARE site which contains information regarding all the vaccines a resident has received.
Should I get the vaccine?
Data from clinical trials indicate that mRNA COVID-19 vaccines are safe in persons with evidence of a prior SARS-CoV-2 infection. Vaccination should be offered to persons regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection. Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection solely for the purposes of vaccine decision-making is not recommended.
Persons with documented acute SARS-CoV-2 infection in the preceding 90 days may delay vaccination until near the end of this period, if desired.
Vaccination of persons with known current SARS-CoV-2 infection should be deferred until the person has recovered from the acute illness (if the person had symptoms) and criteria have been met for them to discontinue isolation.
The only individuals who should not receive mRNA COVID-19 vaccines, such as the recently authorized Pfizer/BioNTech vaccine and Moderna’s similar product, are those with a history of severe allergic reaction, including anaphylaxis, to components of the vaccine. For example, CDC staff highlighted polyethylene glycol, which is often used in laxatives.
A risk assessment and potential deferral of vaccination applies only to those with a history of these severe vaccine-related allergies or severe allergies to other injectable therapies. However, the following groups may proceed with vaccination:
- Individuals with a history of food, pet, insect, venom, environmental, latex, or other allergies unrelated to vaccines or injectable therapies
- History of allergy to oral medications
- Non-serious allergy to vaccines or injectables
- Family history of anaphylaxis
- History of anaphylaxis not related to vaccines or injectable therapy
CDC clinical guidance recommends a 30-minute observation period for those with a history of severe allergic reaction, including anaphylaxis, due to any cause, and a 15-minute period for those with an allergic reaction, but not anaphylaxis.
For those with a history of severe allergies to vaccines or injectable therapies, a 30-minute observation period is recommended.